Positive Results in Phase 3 Trial
On Tuesday, Moderna Inc MRNA announced that mRNA-1283, their cutting-edge COVID-19 vaccine, has exceeded the primary objectives of its Phase 3 trial.
The trial data illustrated a stronger immune response against SARS-CoV-2 compared to mRNA-1273.222, Moderna’s current COVID-19 vaccine.
Moderna’s CEO, Stéphane Bancel, expressed eagerness about the positive Phase 3 results. “mRNA-1283 represents a pivotal aspect of our holistic approach towards a combination vaccine targeting flu and COVID-19, named mRNA-1083. This achievement underscores our confidence in delivering this essential vaccine to the market,” remarked Bancel.
During the NextCOVE Phase 3 pivotal trial, mRNA-1283 exhibited a heightened immune response against both the Omicron BA.4/BA.5 and original strains of the SARS-CoV-2 virus compared to mRNA-1273.222.
The enhanced effectiveness was most apparent among participants aged 65 and above, the age group most vulnerable to severe COVID-19 outcomes.
The prevailing localized adverse reaction was mild discomfort at the injection site. Common systemic side effects included headache, fatigue, myalgia, and chills.
The NEXTCove clinical trial, a randomized, observer-blind, active-controlled study including around 11,400 individuals aged 12 and older, confirmed the similar safety profile of mRNA-1283 to Moderna’s approved COVID-19 vaccines.
Moreover, the storage requirements, extended shelf life, and user-friendly pre-filled syringe presentation of mRNA-1283 could reduce the burden on healthcare providers and potentially broaden access to various settings, enhancing public health efforts.
A comprehensive analysis of the Phase 3 clinical trial data for mRNA-1283 will be unveiled at the Company’s Vaccines Day event on March 27 and presented at forthcoming scientific conferences.
Price Action: MRNA shares saw a 1.36% decline, closing at $108.88 on the latest check on Tuesday.
Photo by Lutsenko_Oleksandr on Shutterstock
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
